Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis.

McGregor NE, Murat M, Elango J, Poulton IJ, Walker EC, Crimeen-Irwin B, Ho PWM, Gooi JH, Martin TJ, Sims NA.

J Biol Chem. 2019 May 10;294(19):7850-7863. doi: 10.1074/jbc.RA119.008074. Epub 2019 Mar 28.

PMID:
30923130
2.

IL-6 trans-signalling mediates trabecular, but not cortical, bone loss after ovariectomy.

Lazzaro L, Tonkin BA, Poulton IJ, McGregor NE, Ferlin W, Sims NA.

Bone. 2018 Jul;112:120-127. doi: 10.1016/j.bone.2018.04.015. Epub 2018 Apr 19.

PMID:
29679733
3.

Osteoblasts Are Rapidly Ablated by Virus-Induced Systemic Inflammation following Lymphocytic Choriomeningitis Virus or Pneumonia Virus of Mice Infection in Mice.

Maltby S, Lochrin AJ, Bartlett B, Tay HL, Weaver J, Poulton IJ, Plank MW, Rosenberg HF, Sims NA, Foster PS.

J Immunol. 2018 Jan 15;200(2):632-642. doi: 10.4049/jimmunol.1700927. Epub 2017 Dec 6.

4.

Bone corticalization requires local SOCS3 activity and is promoted by androgen action via interleukin-6.

Cho DC, Brennan HJ, Johnson RW, Poulton IJ, Gooi JH, Tonkin BA, McGregor NE, Walker EC, Handelsman DJ, Martin TJ, Sims NA.

Nat Commun. 2017 Oct 9;8(1):806. doi: 10.1038/s41467-017-00920-x.

5.

Autocrine and Paracrine Regulation of the Murine Skeleton by Osteocyte-Derived Parathyroid Hormone-Related Protein.

Ansari N, Ho PW, Crimeen-Irwin B, Poulton IJ, Brunt AR, Forwood MR, Divieti Pajevic P, Gooi JH, Martin TJ, Sims NA.

J Bone Miner Res. 2018 Jan;33(1):137-153. doi: 10.1002/jbmr.3291. Epub 2017 Oct 3.

6.

Absence of Calcitriol Causes Increased Lactational Bone Loss and Lower Milk Calcium but Does Not Impair Post-lactation Bone Recovery in Cyp27b1 Null Mice.

Gillies BR, Ryan BA, Tonkin BA, Poulton IJ, Ma Y, Kirby BJ, St-Arnaud R, Sims NA, Kovacs CS.

J Bone Miner Res. 2018 Jan;33(1):16-26. doi: 10.1002/jbmr.3217. Epub 2017 Aug 2.

7.

Correction: Chondrocytic ephrin B2 promotes cartilage destruction by osteoclasts in endochondral ossification.

Tonna S, Poulton IJ, Taykar F, Ho PW, Tonkin B, Crimeen-Irwin B, Tatarczuch L, McGregor NE, Mackie EJ, Martin TJ, Sims NA.

Development. 2017 Feb 1;144(3):530. doi: 10.1242/dev.148460. No abstract available.

8.

Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.

Walker EC, Johnson RW, Hu Y, Brennan HJ, Poulton IJ, Zhang JG, Jenkins BJ, Smyth GK, Nicola NA, Sims NA.

J Biol Chem. 2016 Oct 7;291(41):21703-21716. Epub 2016 Aug 18.

9.

Prepubertal Di-n-Butyl Phthalate Exposure Alters Sertoli and Leydig Cell Function and Lowers Bone Density in Adult Male Mice.

Bielanowicz A, Johnson RW, Goh H, Moody SC, Poulton IJ, Croce N, Loveland KL, Hedger MP, Sims NA, Itman C.

Endocrinology. 2016 Jul;157(7):2595-603. doi: 10.1210/en.2015-1936. Epub 2016 Apr 8.

PMID:
27058814
10.

Chondrocytic ephrin B2 promotes cartilage destruction by osteoclasts in endochondral ossification.

Tonna S, Poulton IJ, Taykar F, Ho PW, Tonkin B, Crimeen-Irwin B, Tatarczuch L, McGregor NE, Mackie EJ, Martin TJ, Sims NA.

Development. 2016 Feb 15;143(4):648-57. doi: 10.1242/dev.125625. Epub 2016 Jan 11. Erratum in: Development. 2017 Feb 1;144(3):530.

11.

Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy.

Sinha P, Aarnisalo P, Chubb R, Poulton IJ, Guo J, Nachtrab G, Kimura T, Swami S, Saeed H, Chen M, Weinstein LS, Schipani E, Sims NA, Kronenberg HM, Wu JY.

J Biol Chem. 2016 Jan 22;291(4):1631-42. doi: 10.1074/jbc.M115.679753. Epub 2015 Nov 23.

12.

Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone.

Johnson RW, McGregor NE, Brennan HJ, Crimeen-Irwin B, Poulton IJ, Martin TJ, Sims NA.

Bone. 2015 Dec;81:343-351. doi: 10.1016/j.bone.2015.08.005. Epub 2015 Aug 7.

PMID:
26255596
13.

RARγ is a negative regulator of osteoclastogenesis.

Green AC, Poulton IJ, Vrahnas C, Häusler KD, Walkley CR, Wu JY, Martin TJ, Gillespie MT, Chandraratna RA, Quinn JM, Sims NA, Purton LE.

J Steroid Biochem Mol Biol. 2015 Jun;150:46-53. doi: 10.1016/j.jsbmb.2015.03.005. Epub 2015 Mar 20.

PMID:
25800721
14.

Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.

Kinross KM, Montgomery KG, Mangiafico SP, Hare LM, Kleinschmidt M, Bywater MJ, Poulton IJ, Vrahnas C, Henneicke H, Malaterre J, Waring PM, Cullinane C, Sims NA, McArthur GA, Andrikopoulos S, Phillips WA.

FASEB J. 2015 Apr;29(4):1426-34. doi: 10.1096/fj.14-262782. Epub 2014 Dec 30.

PMID:
25550458
15.

gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation.

Standal T, Johnson RW, McGregor NE, Poulton IJ, Ho PW, Martin TJ, Sims NA.

J Endocrinol. 2014 Nov;223(2):181-90. doi: 10.1530/JOE-14-0424. Epub 2014 Sep 16.

PMID:
25228504
16.

EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis.

Tonna S, Takyar FM, Vrahnas C, Crimeen-Irwin B, Ho PW, Poulton IJ, Brennan HJ, McGregor NE, Allan EH, Nguyen H, Forwood MR, Tatarczuch L, Mackie EJ, Martin TJ, Sims NA.

FASEB J. 2014 Oct;28(10):4482-96. doi: 10.1096/fj.14-254300. Epub 2014 Jun 30. Erratum in: FASEB J. 2017 Mar;31(3):1249.

PMID:
24982128
17.

The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation.

Johnson RW, Brennan HJ, Vrahnas C, Poulton IJ, McGregor NE, Standal T, Walker EC, Koh TT, Nguyen H, Walsh NC, Forwood MR, Martin TJ, Sims NA.

J Bone Miner Res. 2014 Jun;29(6):1492-505. doi: 10.1002/jbmr.2159.

18.

Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in ptpn2-deficient mice.

Wiede F, Chew SH, van Vliet C, Poulton IJ, Kyparissoudis K, Sasmono T, Loh K, Tremblay ML, Godfrey DI, Sims NA, Tiganis T.

PLoS One. 2012;7(5):e36703. doi: 10.1371/journal.pone.0036703. Epub 2012 May 8.

19.

Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.

Walker EC, Poulton IJ, McGregor NE, Ho PW, Allan EH, Quach JM, Martin TJ, Sims NA.

J Bone Miner Res. 2012 Apr;27(4):902-12. doi: 10.1002/jbmr.1506.

20.

Contrasting roles of leukemia inhibitory factor in murine bone development and remodeling involve region-specific changes in vascularization.

Poulton IJ, McGregor NE, Pompolo S, Walker EC, Sims NA.

J Bone Miner Res. 2012 Mar;27(3):586-95. doi: 10.1002/jbmr.1485.

21.

Gsα enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice.

Wu JY, Aarnisalo P, Bastepe M, Sinha P, Fulzele K, Selig MK, Chen M, Poulton IJ, Purton LE, Sims NA, Weinstein LS, Kronenberg HM.

J Clin Invest. 2011 Sep;121(9):3492-504. doi: 10.1172/JCI46406. Epub 2011 Aug 1.

22.

Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice.

Menkhorst E, Zhang JG, Sims NA, Morgan PO, Soo P, Poulton IJ, Metcalf D, Alexandrou E, Gresle M, Salamonsen LA, Butzkueven H, Nicola NA, Dimitriadis E.

PLoS One. 2011;6(5):e19665. doi: 10.1371/journal.pone.0019665. Epub 2011 May 18.

23.

Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs.

Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, Poulton IJ, van Rooijen N, Alexander KA, Raggatt LJ, Lévesque JP.

Blood. 2010 Dec 2;116(23):4815-28. doi: 10.1182/blood-2009-11-253534. Epub 2010 Aug 16.

PMID:
20713966
24.

Severe developmental bone phenotype in ClC-7 deficient mice.

Neutzsky-Wulff AV, Sims NA, Supanchart C, Kornak U, Felsenberg D, Poulton IJ, Martin TJ, Karsdal MA, Henriksen K.

Dev Biol. 2010 Aug 15;344(2):1001-10. doi: 10.1016/j.ydbio.2010.06.018. Epub 2010 Jun 22.

25.

Adverse effects of valproate on bone: defining a model to investigate the pathophysiology.

Senn SM, Kantor S, Poulton IJ, Morris MJ, Sims NA, O'Brien TJ, Wark JD.

Epilepsia. 2010 Jun;51(6):984-93. doi: 10.1111/j.1528-1167.2009.02516.x. Epub 2010 Feb 12.

26.

Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling.

McGregor NE, Poulton IJ, Walker EC, Pompolo S, Quinn JM, Martin TJ, Sims NA.

Calcif Tissue Int. 2010 Mar;86(3):261-70. doi: 10.1007/s00223-010-9337-4. Epub 2010 Feb 16. Erratum in: Calcif Tissue Int. 2013 May;92(5):493.

PMID:
20157807
27.

Lack of sustained response to teriparatide in a patient with adult hypophosphatasia.

Gagnon C, Sims NA, Mumm S, McAuley SA, Jung C, Poulton IJ, Ng KW, Ebeling PR.

J Clin Endocrinol Metab. 2010 Mar;95(3):1007-12. doi: 10.1210/jc.2009-1965. Epub 2010 Jan 20.

PMID:
20089612
28.

Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice.

Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, Fernandes TJ, Constable MJ, Nicholson GC, Zhang JG, Nicola NA, Gillespie MT, Martin TJ, Sims NA.

J Clin Invest. 2010 Feb;120(2):582-92. doi: 10.1172/JCI40568. Epub 2010 Jan 4.

29.

Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function.

Quinn JM, Tam S, Sims NA, Saleh H, McGregor NE, Poulton IJ, Scott JW, Gillespie MT, Kemp BE, van Denderen BJ.

FASEB J. 2010 Jan;24(1):275-85. doi: 10.1096/fj.09-137158. Epub 2009 Sep 1.

30.

Osteoclast inhibitory lectin, an immune cell product that is required for normal bone physiology in vivo.

Kartsogiannis V, Sims NA, Quinn JM, Ly C, Cipetic M, Poulton IJ, Walker EC, Saleh H, McGregor NE, Wallace ME, Smyth MJ, Martin TJ, Zhou H, Ng KW, Gillespie MT.

J Biol Chem. 2008 Nov 7;283(45):30850-60. doi: 10.1074/jbc.M801761200. Epub 2008 Sep 8.

31.

Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling.

Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, Quinn JM, Gillespie MT, Martin TJ, Sims NA.

J Bone Miner Res. 2008 Dec;23(12):2025-32. doi: 10.1359/jbmr.080706.

Supplemental Content

Loading ...
Support Center